Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SRPT Stock Forecast 2026-2027
$15.75
Current Price
$1.66B
Market Cap
Buy 6
Hold 13
Sell 5
Wall St Analyst Ratings
Distance to SRPT Price Targets
+141.3%
To High Target of $38.00
+27.0%
To Median Target of $20.00
-68.3%
To Low Target of $5.00
SRPT Price Momentum
-11.9%
1 Week Change
-31.6%
1 Month Change
-63.4%
1 Year Change
-26.8%
Year-to-Date Change
-64.1%
From 52W High of $43.92
+51.2%
From 52W Low of $10.42
📊 TOP ANALYST CALLS
Did SRPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sarepta is one of their latest high-conviction picks.
Latest SRPT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, SRPT has a neutral consensus with a median price target of $20.00 (ranging from $5.00 to $38.00). The overall analyst rating is Buy (6.3/10). Currently trading at $15.75, the median forecast implies a 27.0% upside. This outlook is supported by 6 Buy, 13 Hold, and 5 Sell ratings.
Conversely, the most conservative target is provided by Mitchell S. Kapoor at HC Wainwright & Co., suggesting a 68.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRPT Analyst Ratings
6
Buy
13
Hold
5
Sell
SRPT Price Target Range
Low
$5.00
Average
$20.00
High
$38.00
Current: $15.75
Latest SRPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Sell | Reiterates | $5.00 |
| Mar 26, 2026 | Citigroup | Sell | Maintains | $N/A | |
| Mar 26, 2026 | Needham | Underperform | Reiterates | $N/A | |
| Mar 19, 2026 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Mar 13, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Mar 10, 2026 | Citigroup | Sell | Maintains | $N/A | |
| Mar 2, 2026 | HC Wainwright & Co. | Sell | Reiterates | $N/A | |
| Feb 27, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Jan 27, 2026 | HC Wainwright & Co. | Sell | Reiterates | $N/A | |
| Jan 23, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Jan 14, 2026 | HC Wainwright & Co. | Sell | Reiterates | $N/A | |
| Dec 9, 2025 | Wedbush | Outperform | Initiates | $N/A | |
| Nov 5, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Nov 5, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Nov 5, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Nov 5, 2025 | Mizuho | Outperform | Upgrade | $N/A | |
| Nov 4, 2025 | Baird | Neutral | Maintains | $N/A | |
| Oct 30, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Sep 22, 2025 | BMO Capital | Outperform | Upgrade | $N/A | |
| Sep 15, 2025 | Guggenheim | Buy | Reiterates | $N/A |
Sarepta Therapeutics Inc. (SRPT) Competitors
The following stocks are similar to Sarepta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sarepta Therapeutics Inc. (SRPT) Financial Data
Sarepta Therapeutics Inc. has a market capitalization of $1.66B with a P/E ratio of 45.0x. The company generates $2.18B in trailing twelve-month revenue with a 3.0% profit margin.
Revenue growth is -1.9% quarter-over-quarter, while maintaining an operating margin of +49.0% and return on equity of +4.9%.
Valuation Metrics
Market Cap
$1.66B
Enterprise Value
$2.06B
P/E Ratio
45.0x
PEG Ratio
-0.3x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
-1.9%
Gross Margin
+85.1%
Operating Margin
+49.0%
Net Margin
+3.0%
EPS Growth
-1.9%
Financial Health
Cash/Price Ratio
+39.3%
Current Ratio
4.6x
Debt/Equity
69.6x
ROE
+4.9%
ROA
+0.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sarepta Therapeutics Inc. (SRPT) Business Model
About Sarepta Therapeutics Inc.
What They Do
Develops precision genetic medicines for rare diseases.
Business Model
Sarepta Therapeutics Inc. operates as a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of RNA-targeted therapeutics and gene therapies. It generates revenue through the sale of its key products, which include treatments specifically designed for Duchenne muscular dystrophy (DMD), targeting various genetic mutations through advanced therapies.
Additional Information
The company has a robust pipeline of investigational therapies for additional rare neuromuscular and central nervous system disorders, emphasizing innovative exon-skipping technologies. Established in 1980 and based in Cambridge, Massachusetts, Sarepta Therapeutics is committed to addressing the needs of patients with limited treatment options and aims to expand access to its specialized therapies through ongoing clinical research.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
835
CEO
Mr. Douglas S. Ingram Esq., J.D.
Country
United States
IPO Year
1997
Website
www.sarepta.comSarepta Therapeutics Inc. (SRPT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Sarepta Therapeutics (NASDAQ:SRPT) will participate in investor conferences in June: Goldman Sachs on June 8 and Oppenheimer on June 10, 2026, focusing on healthcare and neuromuscular topics.
Why It Matters
Sarepta Therapeutics' participation in key investor conferences signals potential updates on their pipeline and strategic direction, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sarepta Therapeutics (NASDAQ:SRPT) will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20 at 8:30 a.m. ET, available via webcast on its investor relations site.
Why It Matters
Sarepta Therapeutics’ participation in a major healthcare conference signals potential updates on its projects, which could affect stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sarepta stock declined as investors reacted to the sales performance of its gene therapy, Elevidys, which exceeded expectations but remains under scrutiny.
Why It Matters
Sarepta's stock decline indicates market skepticism about Elevidys' commercial viability, impacting future revenue forecasts and investor confidence.
Source: Investors Business Daily
Market Sentiment:
Negative
Quick Summary
Sarepta Therapeutics, Inc. (SRPT) held its Q1 2026 earnings call, discussing financial performance and updates on its pipeline and clinical trials.
Why It Matters
Sarepta's Q1 2026 earnings call reveals financial performance, updates on drug development, and future guidance, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
30 days ago
Quick Summary
Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 2026 financial results, focusing on stabilizing the business, restoring growth, and advancing its pipeline under CEO Doug Ingram's leadership.
Why It Matters
Sarepta's focus on stabilizing business and advancing its pipeline signals potential for growth, influencing investor confidence and stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sarepta Therapeutics (SRPT) reported Q3 earnings of $3.16 per share, surpassing estimates of $0.90, and improved from a loss of $3.42 per share a year prior.
Why It Matters
Sarepta's significant earnings beat signals strong financial performance and growth potential, positively influencing investor sentiment and possibly driving stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About SRPT Stock
What is Sarepta Therapeutics Inc.'s (SRPT) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Sarepta Therapeutics Inc. (SRPT) has a median price target of $20.00. The highest price target is $38.00 and the lowest is $5.00.
Is SRPT stock a good investment in 2026?
According to current analyst ratings, SRPT has 6 Buy ratings, 13 Hold ratings, and 5 Sell ratings. The stock is currently trading at $15.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SRPT stock?
Wall Street analysts predict SRPT stock could reach $20.00 in the next 12 months. This represents a 27.0% increase from the current price of $15.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sarepta Therapeutics Inc.'s business model?
Sarepta Therapeutics Inc. operates as a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of RNA-targeted therapeutics and gene therapies. It generates revenue through the sale of its key products, which include treatments specifically designed for Duchenne muscular dystrophy (DMD), targeting various genetic mutations through advanced therapies.
What is the highest forecasted price for SRPT Sarepta Therapeutics Inc.?
The highest price target for SRPT is $38.00 from at , which represents a 141.3% increase from the current price of $15.75.
What is the lowest forecasted price for SRPT Sarepta Therapeutics Inc.?
The lowest price target for SRPT is $5.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a -68.3% decrease from the current price of $15.75.
What is the overall SRPT consensus from analysts for Sarepta Therapeutics Inc.?
The overall analyst consensus for SRPT is neutral. Out of 3 Wall Street analysts, 6 rate it as Buy, 13 as Hold, and 5 as Sell, with a median price target of $20.00.
How accurate are SRPT stock price projections?
Stock price projections, including those for Sarepta Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 12:00 PM UTC